Population-minded testing Coyne Scientific offers in vitro toxicity assays using human iPSCs from large donor cohorts to capture population-level variability, presenting a compelling value proposition for pharma companies aiming to de-risk candidates early in development and improve success rates in later trials.

Early risk mitigation Their approach enables pharmaceutical sponsors to potentially curtail investment in compounds with unfavorable safety signals before animal studies, while preserving promising drugs that might be misclassified as high risk in traditional single-donor tests.

Strategic partnerships CoyneSci’s active involvement with Safety Pharmacology Society, Society of Toxicology, and other industry bodies signals credibility and provides networking channels to secure pilot programs, co-development opportunities, and validated reference accounts.

New facility advantage Operates from a newly opened, highly automated 6,500 sq ft lab in Atlanta, highlighting capacity for scalable testing, faster turnaround, and the potential to handle multiple client programs concurrently.

Emerging market fit With a sub-$1M annual revenue profile and specialized regenerative toxicology services, CoyneSci is positioned to win mid-market pharmaceutical or biotech clients seeking advanced, population-representative safety assessments and cost-efficient drug development insights.